Ally Bridge Group NY LLC Acquires 533,023 Shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN)
by Kim Johansen · The Markets DailyAlly Bridge Group NY LLC increased its stake in shares of ProMIS Neurosciences, Inc. (NASDAQ:PMN – Free Report) by 50.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,592,605 shares of the company’s stock after acquiring an additional 533,023 shares during the quarter. ProMIS Neurosciences comprises approximately 1.1% of Ally Bridge Group NY LLC’s holdings, making the stock its 29th largest holding. Ally Bridge Group NY LLC owned 5.33% of ProMIS Neurosciences worth $1,991,000 as of its most recent SEC filing.
Separately, Great Point Partners LLC bought a new stake in shares of ProMIS Neurosciences in the 3rd quarter worth approximately $3,488,000. Institutional investors own 50.13% of the company’s stock.
Insider Buying and Selling
In other ProMIS Neurosciences news, Director Madge K. Shafmaster bought 60,000 shares of the stock in a transaction that occurred on Friday, September 20th. The shares were acquired at an average price of $1.25 per share, with a total value of $75,000.00. Following the completion of the purchase, the director now directly owns 68,333 shares in the company, valued at $85,416.25. The trade was a 720.03 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.40% of the stock is owned by company insiders.
ProMIS Neurosciences Trading Up 2.2 %
Shares of NASDAQ:PMN opened at $0.94 on Thursday. The business’s 50 day moving average is $1.07 and its 200-day moving average is $1.41. The firm has a market capitalization of $30.73 million, a PE ratio of -9.40 and a beta of 0.60. ProMIS Neurosciences, Inc. has a 1-year low of $0.88 and a 1-year high of $3.10.
ProMIS Neurosciences Company Profile
ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.
Read More
- Five stocks we like better than ProMIS Neurosciences
- Investing in Construction Stocks
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- 3 Warren Buffett Stocks to Buy Now
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- What Are Dividend Achievers? An Introduction
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ